Kestra Medical Technologies (NASDAQ:KMTS) Trading 7.5% Higher – What’s Next?

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS)’s share price traded up 7.5% during mid-day trading on Wednesday . The company traded as high as $26.47 and last traded at $27.36. Approximately 17,413 shares changed hands during trading, a decline of 95% from the average daily volume of 327,786 shares. The stock had previously closed at $25.44.

Analyst Upgrades and Downgrades

KMTS has been the topic of several recent research reports. BTIG Research reiterated a “buy” rating and issued a $32.00 price objective on shares of Kestra Medical Technologies in a research note on Tuesday, April 7th. The Goldman Sachs Group reduced their target price on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a report on Thursday, April 9th. Wall Street Zen upgraded shares of Kestra Medical Technologies from a “sell” rating to a “hold” rating in a research note on Saturday, June 27th. Finally, Weiss Ratings upgraded Kestra Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $27.40.

Kestra Medical Technologies Trading Up 2.7%

The stock has a 50-day moving average price of $21.33 and a two-hundred day moving average price of $22.79. The stock has a market capitalization of $1.57 billion, a PE ratio of -6.81 and a beta of 0.47. The company has a debt-to-equity ratio of 0.15, a quick ratio of 7.32 and a current ratio of 7.32.

Insider Buying and Selling

In other Kestra Medical Technologies news, insider Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $20.81, for a total transaction of $312,150.00. Following the transaction, the insider owned 395,467 shares of the company’s stock, valued at $8,229,668.27. The trade was a 3.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders have sold 45,000 shares of company stock worth $927,150. 3.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Kestra Medical Technologies

Institutional investors have recently bought and sold shares of the business. California State Teachers Retirement System lifted its position in shares of Kestra Medical Technologies by 39.2% in the first quarter. California State Teachers Retirement System now owns 27,835 shares of the company’s stock valued at $555,000 after acquiring an additional 7,844 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Kestra Medical Technologies by 6.6% during the first quarter. The Manufacturers Life Insurance Company now owns 92,515 shares of the company’s stock worth $1,844,000 after purchasing an additional 5,731 shares in the last quarter. Quantinno Capital Management LP bought a new stake in Kestra Medical Technologies during the 1st quarter valued at approximately $431,000. Sei Investments Co. lifted its holdings in Kestra Medical Technologies by 22.6% in the 1st quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock worth $4,726,000 after purchasing an additional 43,753 shares in the last quarter. Finally, Spartan Wealth Advisory Services LLC purchased a new position in Kestra Medical Technologies in the 1st quarter worth approximately $603,000.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.